Clinical Trial Update: Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of Tozadenant for end of dose wearing off in Parkinson's disease was terminated, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Parkinson Disease

Drugs mentioned

• Tozadenant (tozadenant)

Snippet

Sponsor: Biotie Therapies Inc. | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: TERMINATED | Results posted: 2019-03-26